About Oxygenta Pharmaceutical Limited
Data last updated: 17 February 2026
Oxygenta Pharmaceutical Limited is a public limited company based in Medak, Telangana, India. It specialises in organic chemicals and compounds, a part of the broader chemicals and materials sector. Incorporated on 27 November 1990, the company has been in operation for over 36 years.
Registered with ROC Hyderabad under CIN L24110TG1990PLC012038. Listed on BSE: 524636.
Capital: an authorised share capital of ₹37.5 Cr and a paid-up capital of ₹36.98 Cr. Formerly known as S.S. Organics Pvt Ltd and S.S. Organics Ltd. It is led by directors including Vedavathi Gangavaram and Chandra Mouliswar Reddy Gangavaram.
Last AGM: 19 September 2025. Financial statements filed for year ended 31 March 2025. Office: Survey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India.
As per the financials filed for FY 2023, the company reported a revenue of ₹31.01 Cr, a decline of 48.78% compared to the previous year.
The company has a workforce of approximately 98 employees as per the latest available data.
The company is associated with 2 brands - Oxygenta Pharmaceutical Ltd, S S Organics. As per MCA filings, the company has open charges of ₹46.6 Cr and satisfied charges of ₹55.7 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website oxygentapharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressSurvey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India
-
IndustryChemicals and Materials, Organic Chemicals & Compounds
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has undergone 2 name changes throughout its history. The company was previously known as S.S. Organics Pvt Ltd, and S.S. Organics Ltd.. The current legal name is Oxygenta Pharmaceutical Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Oxygenta Pharmaceutical Limited | Current |
| S.S. Organics Pvt Ltd | Previous |
| S.S. Organics Ltd. | Previous |
CIN History of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has one previous CIN (Corporate Identification Number): L24110AP1990PLC012038. The current CIN is L24110TG1990PLC012038, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1990PLC012038 | Current |
| L24110AP1990PLC012038 | Previous |
Associated Brands with Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited operates two associated brands: Oxygenta Pharmaceutical Ltd and S S ORGANICS. These brands represent Oxygenta Pharmaceutical Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Finished products and APIs are manufactured for therapeutic categories. | ssorganics.co.in | |
| Manufacturing of drugs, pharmaceutical preparations, and organic fine chemicals in India. | oxygentapharma.com |
Competitors & Alternatives of Oxygenta Pharmaceutical Limited
Brands and companies operating in the same space as Oxygenta Pharmaceutical Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is audited by M/s. A.M. Reddy & D.R. Reddy (ICAI peer reviewed, certificate valid till 2027-02-28) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s. A.M. Reddy & D.R. Reddy (ICAI peer reviewed, certificate valid till 2027-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is currently managed by 8 directors, with 47 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Oxygenta Pharmaceutical Limited FY 2026 filings available
Oxygenta Pharmaceutical Limited reported revenue of ₹112.98 Cr (up 3.37% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹112.98 Cr | ₹109.3 Cr | ₹39.64 Cr | ₹30.99 Cr | ₹60.52 Cr | ₹52.03 Cr | ₹13.72 Cr | ₹20.51 Cr |
| Other Income | ₹28.58 Lakh | ₹1.31 Cr | ₹4.24 Lakh | ₹1.78 Lakh | ₹45,000 | ₹9.12 Lakh | ₹3.36 Lakh | ₹1.3 Lakh |
| Total Income | ₹113.27 Cr | ₹110.61 Cr | ₹39.68 Cr | ₹31.01 Cr | ₹60.53 Cr | ₹52.12 Cr | ₹13.75 Cr | ₹20.52 Cr |
| Cost of Materials Consumed | ₹110.34 Cr | ₹100.23 Cr | ₹35.06 Cr | ₹28.13 Cr | ₹42.67 Cr | ₹43.02 Cr | ₹14.99 Cr | ₹17.75 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹8.2 Cr | -₹3.76 Cr | -₹1.53 Cr | -₹4.63 Cr | ₹4.55 Cr | -₹6.39 Cr | ₹58.88 Lakh | -₹1.67 Cr |
| Employee Benefit Expense | ₹7.64 Cr | ₹6.9 Cr | ₹5.99 Cr | ₹1.12 Cr | ₹33.04 Lakh | ₹73.28 Lakh | ₹60.45 Lakh | ₹80.22 Lakh |
| Finance Costs | ₹4.78 Cr | ₹3.61 Cr | ₹1.59 Cr | ₹1.49 Cr | ₹92.49 Lakh | ₹1.78 Cr | ₹1.09 Cr | ₹74.6 Lakh |
| Depreciation & Amortisation | ₹2.32 Cr | ₹1.78 Cr | ₹2.66 Cr | ₹2.05 Cr | ₹1.59 Cr | ₹1.2 Cr | ₹99.85 Lakh | ₹1.02 Cr |
| Other Expenses | ₹18.57 Cr | ₹15.92 Cr | ₹9.82 Cr | ₹13.49 Cr | ₹11.5 Cr | ₹10.82 Cr | ₹5.4 Cr | ₹5.67 Cr |
| Total Expenses | ₹135.45 Cr | ₹124.69 Cr | ₹53.59 Cr | ₹41.64 Cr | ₹61.57 Cr | ₹51.16 Cr | ₹23.68 Cr | ₹24.31 Cr |
| Profit Before Exceptional Items & Tax | -₹22.18 Cr | -₹14.08 Cr | -₹13.91 Cr | -₹10.64 Cr | -₹1.04 Cr | ₹95.51 Lakh | -₹9.93 Cr | -₹3.79 Cr |
| Exceptional Items | ₹0 | -₹27 Lakh | ₹3.7 Lakh | -₹73.44 Lakh | ₹54.64 Lakh | ₹2.19 Cr | ₹3.99 Cr | ₹30.1 Lakh |
| Profit Before Tax | -₹22.18 Cr | -₹14.35 Cr | -₹13.87 Cr | -₹11.37 Cr | -₹48.94 Lakh | ₹3.14 Cr | -₹5.94 Cr | -₹3.49 Cr |
| Total Tax Expense | -₹4.61 Cr | -₹4.05 Cr | -₹10.39 Cr | ₹19.83 Lakh | ₹12.11 Lakh | ₹21.39 Lakh | -₹15.32 Lakh | -₹23.9 Lakh |
| Net Profit | -₹17.57 Cr | -₹10.3 Cr | -₹3.48 Cr | -₹11.57 Cr | -₹61.05 Lakh | ₹2.93 Cr | -₹5.79 Cr | -₹3.25 Cr |
| Other Comprehensive Income | ₹52.54 Lakh | -₹10.73 Lakh | ₹7.11 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹17.05 Cr | -₹10.41 Cr | -₹3.41 Cr | -₹11.57 Cr | -₹61.05 Lakh | ₹2.93 Cr | -₹5.79 Cr | -₹3.25 Cr |
| EBITDA (computed) | -₹15.08 Cr | -₹8.69 Cr | -₹9.65 Cr | -₹7.1 Cr | ₹1.48 Cr | ₹3.93 Cr | -₹7.83 Cr | -₹2.03 Cr |
| Basic EPS | ₹-4.75 | ₹-2.86 | ₹-1.09 | ₹-6.36 | ₹-0.48 | ₹2.87 | ₹-5.67 | ₹-3.19 |
| Diluted EPS | ₹-4.75 | ₹-2.86 | ₹-1.04 | ₹-6.36 | ₹-0.48 | ₹2.87 | ₹-5.67 | ₹-3.19 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹119.68 Cr | ₹82.8 Cr | ₹63.19 Cr | ₹54.26 Cr | ₹31.18 Cr | ₹34.02 Cr | ₹18.62 Cr | ₹21.16 Cr |
| Non-current Assets | ₹68.25 Cr | ₹51.86 Cr | ₹39.09 Cr | ₹29.26 Cr | ₹21.91 Cr | ₹17.92 Cr | ₹11.85 Cr | ₹12.35 Cr |
| Current Assets | ₹51.43 Cr | ₹30.94 Cr | ₹24.11 Cr | ₹25.01 Cr | ₹9.16 Cr | ₹16.1 Cr | ₹6.77 Cr | ₹8.8 Cr |
| Property, Plant & Equipment | ₹47.6 Cr | ₹36.83 Cr | ₹29.36 Cr | ₹27.91 Cr | ₹19.98 Cr | ₹16.31 Cr | ₹11.42 Cr | ₹11.9 Cr |
| Inventories | ₹29.42 Cr | ₹20.51 Cr | ₹13.72 Cr | ₹11.71 Cr | ₹7.28 Cr | ₹12.11 Cr | ₹4.25 Cr | ₹5.33 Cr |
| Trade Receivables | ₹10.03 Cr | ₹5.1 Cr | ₹7.36 Cr | ₹10.16 Cr | ₹1.27 Cr | ₹1.61 Cr | ₹42.37 Lakh | ₹51.49 Lakh |
| Cash & Equivalents | ₹41.9 Lakh | ₹17,000 | ₹17,000 | ₹1.75 Lakh | ₹15.57 Lakh | ₹44.5 Lakh | ₹11.83 Lakh | ₹1.86 Lakh |
| Equity (Net Worth) | -₹42.69 Cr | -₹25.64 Cr | -₹20.12 Cr | -₹46.2 Cr | -₹34.63 Cr | -₹38.02 Cr | -₹40.95 Cr | -₹35.16 Cr |
| Equity Share Capital | ₹36.98 Cr | ₹36.98 Cr | ₹33.48 Cr | ₹14.2 Cr | ₹14.2 Cr | ₹10.2 Cr | ₹10.2 Cr | ₹10.2 Cr |
| Borrowings (Non-current) | ₹75.29 Cr | ₹21.52 Cr | ₹49 Cr | ₹63.02 Cr | ₹51.04 Cr | ₹45.04 Cr | ₹25.44 Cr | ₹20.87 Cr |
| Borrowings (Current) | ₹34.28 Cr | ₹40.71 Cr | ₹8.23 Cr | ₹4.97 Cr | ₹1.09 Cr | ₹2.85 Cr | ₹49.64 Lakh | ₹48.82 Lakh |
| Total Debt (computed) | ₹109.57 Cr | ₹62.23 Cr | ₹57.23 Cr | ₹67.99 Cr | ₹52.13 Cr | ₹47.89 Cr | ₹25.94 Cr | ₹21.36 Cr |
| Current Liabilities | ₹86.1 Cr | ₹85.85 Cr | ₹33.7 Cr | ₹26.04 Cr | ₹6.79 Cr | ₹19.01 Cr | ₹15.85 Cr | ₹16.73 Cr |
| Total Liabilities | ₹162.37 Cr | ₹108.44 Cr | ₹83.31 Cr | ₹100.46 Cr | ₹65.81 Cr | ₹72.04 Cr | ₹59.57 Cr | ₹56.32 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹27.75 Cr | ₹2.6 Cr | -₹13.05 Cr | -₹5.41 Cr | -₹2.93 Cr |
| Investing Cash Flow | -₹14.39 Cr | -₹11.25 Cr | -₹4.09 Cr | -₹9.64 Cr | -₹4.94 Cr |
| Financing Cash Flow | ₹42.56 Cr | ₹8.67 Cr | ₹17.13 Cr | ₹15 Cr | ₹7.58 Cr |
| Capital Expenditure | ₹12.86 Cr | ₹11.39 Cr | ₹4.11 Cr | ₹9.64 Cr | ₹4.95 Cr |
| Free Cash Flow (computed) | -₹40.61 Cr | -₹8.79 Cr | -₹17.16 Cr | -₹15.05 Cr | -₹7.87 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹41.73 Lakh | ₹2.09 Lakh | -₹54,000 | -₹4.94 Lakh | -₹28.93 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹49.61 Cr | ₹33.93 Cr | ₹14.3 Cr | ₹15.13 Cr | ₹49.47 Cr | ₹33.21 Cr | ₹14.01 Cr | ₹12.62 Cr |
| Other Income | ₹17.29 Lakh | ₹0 | -₹5.62 Lakh | ₹16.91 Lakh | ₹4.91 Lakh | ₹48.82 Lakh | ₹74.93 Lakh | ₹2.25 Lakh |
| Total Income | ₹49.79 Cr | ₹33.93 Cr | ₹14.25 Cr | ₹15.3 Cr | ₹49.52 Cr | ₹33.69 Cr | ₹14.75 Cr | ₹12.64 Cr |
| Cost of Materials Consumed | ₹46.54 Cr | ₹31.17 Cr | ₹16.97 Cr | ₹15.66 Cr | ₹44.03 Cr | ₹37.61 Cr | ₹7.94 Cr | ₹10.66 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹3.34 Cr | ₹36.98 Lakh | -₹4.53 Cr | -₹70.34 Lakh | -₹24.34 Lakh | -₹5.76 Cr | ₹2.9 Cr | -₹65.9 Lakh |
| Employee Benefit Expense | ₹1.72 Cr | ₹1.89 Cr | ₹2.03 Cr | ₹2 Cr | ₹2.19 Cr | ₹1.83 Cr | ₹1.4 Cr | ₹1.48 Cr |
| Finance Costs | ₹1.81 Cr | ₹1.39 Cr | ₹94.96 Lakh | ₹62.84 Lakh | ₹2.13 Cr | ₹38.83 Lakh | ₹69.09 Lakh | ₹40.68 Lakh |
| Depreciation & Amortisation | -₹24.11 Lakh | ₹85.92 Lakh | ₹85.71 Lakh | ₹84.73 Lakh | -₹23.37 Lakh | ₹70.6 Lakh | ₹65.99 Lakh | ₹64.94 Lakh |
| Other Expenses | ₹4.58 Cr | ₹4.58 Cr | ₹4.41 Cr | ₹5.01 Cr | ₹5.17 Cr | ₹3.88 Cr | ₹3.94 Cr | ₹2.92 Cr |
| Total Expenses | ₹51.07 Cr | ₹40.26 Cr | ₹20.68 Cr | ₹23.44 Cr | ₹53.04 Cr | ₹38.66 Cr | ₹17.53 Cr | ₹15.46 Cr |
| Profit Before Exceptional Items & Tax | -₹1.28 Cr | -₹6.33 Cr | -₹6.44 Cr | -₹8.14 Cr | -₹3.53 Cr | -₹4.96 Cr | -₹2.77 Cr | -₹2.82 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | -₹1.18 Lakh | -₹27 Lakh | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.28 Cr | -₹6.33 Cr | -₹6.44 Cr | -₹8.15 Cr | -₹3.8 Cr | -₹4.96 Cr | -₹2.77 Cr | -₹2.82 Cr |
| Total Tax Expense | ₹42.42 Lakh | -₹1.48 Cr | -₹1.51 Cr | -₹2.04 Cr | -₹1.65 Cr | -₹1.03 Cr | ₹8.05 Lakh | -₹1.45 Cr |
| Net Profit | -₹1.7 Cr | -₹4.84 Cr | -₹4.93 Cr | -₹6.11 Cr | -₹2.15 Cr | -₹3.93 Cr | -₹2.85 Cr | -₹1.36 Cr |
| Other Comprehensive Income | ₹52.54 Lakh | ₹0 | ₹0 | ₹0 | -₹10.73 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.18 Cr | -₹4.84 Cr | -₹4.93 Cr | -₹6.11 Cr | -₹2.26 Cr | -₹3.93 Cr | -₹2.85 Cr | -₹1.36 Cr |
| EBITDA (computed) | ₹28.72 Lakh | -₹4.08 Cr | -₹4.63 Cr | -₹6.66 Cr | -₹1.63 Cr | -₹3.87 Cr | -₹1.42 Cr | -₹1.76 Cr |
| Basic EPS | ₹-0.45 | ₹-1.32 | ₹-1.33 | ₹-1.65 | ₹-0.60 | ₹1.07 | ₹-0.81 | ₹0.39 |
| Diluted EPS | ₹-0.45 | ₹-1.32 | ₹-1.33 | ₹-1.65 | ₹-0.60 | ₹1.12 | ₹-0.78 | ₹0.37 |
Shareholding Pattern of Oxygenta Pharmaceutical Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 56.54%, domestic institutional investors hold 0.03%, retail and other public shareholders hold 43.44% of Oxygenta Pharmaceutical Limited. The company had 10,205 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 56.54% | 55.93% | 57.95% | 57.95% | 51.12% | 51.12% |
| Public | 43.46% | 44.07% | 42.05% | 42.05% | 48.88% | 48.88% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 56.54% | 51.12% | 29.73% |
| Public | 43.46% | 48.88% | 70.27% |
| Promoter change (YoY, %pts) | +5.42 | +21.39 | - |
Charges & Borrowings of Oxygenta Pharmaceutical Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2025 | Others | ₹46.6 Cr | Open |
| 02 Sep 2022 | Others | ₹5 Cr | Satisfied |
| 02 Sep 2022 | Others | ₹10 Cr | Satisfied |
| 21 Dec 2020 | Others | ₹6.7 Cr | Satisfied |
| 10 Sep 2020 | Others | ₹31.5 Cr | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has a workforce of 98 employees as of Sep 11, 2024.
Employee Count & EPFO Data of Oxygenta Pharmaceutical Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Oxygenta Pharmaceutical Limited
GSTIN & GST Filing Data of Oxygenta Pharmaceutical Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Oxygenta Pharmaceutical Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Oxygenta Pharmaceutical Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Oxygenta Pharmaceutical Limited
MSME Payment Delays by Oxygenta Pharmaceutical Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Oxygenta Pharmaceutical Limited
Subsidiaries & Group Companies of Oxygenta Pharmaceutical Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Oxygenta Pharmaceutical Limited with ownership details.
MCA Filings & Documents of Oxygenta Pharmaceutical Limited
MCA Filings & Documents of Oxygenta Pharmaceutical Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Oxygenta Pharmaceutical Limited
Frequently Asked Questions about Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is an active public limited company in the chemicals and materials sector based in Medak, Telangana, India. It was incorporated on 27 November 1990 (36+ years old) and is registered under CIN L24110TG1990PLC012038. Listed on BSE: 524636. The company has 98 employees.
Oxygenta Pharmaceutical Limited reported revenue of ₹31.01 Cr for FY 2023 (down 48.78% YoY).
The current directors of Oxygenta Pharmaceutical Limited are:
- Vedavathi Gangavaram
- Chandra Mouliswar Reddy Gangavaram
- Sidda Reddy Kanuparthi
- Balasubba Reddy Mamilla
- Veera Reddy Arava
- Sharvari Swapnil Shinde
- Kumkum Bajaj
- Prasad Reddy Battinapatla
The primary industry of Oxygenta Pharmaceutical Limited is chemicals and materials. The company specifically operates in organic chemicals and compounds. The company is currently active in this sector.
Yes. Oxygenta Pharmaceutical Limited is listed on BSE with code 524636.
Oxygenta Pharmaceutical Limited can be reached at the registered office: Survey No.2521 Aroor Village Sadasivapet Mandal Medak District, Telangana, India, or through the website oxygentapharma.com.